Moncef Slaoui speaks with President Donald Trump about Operation Warp Speed in the Rose Garden of the White House on Friday November 13, 2020 in Washington, DC.
Jabin Botsford | The Washington Post | Getty Images
Moncef Slaoui, the was chief scientist with the US federal government Covid vaccine development effort, Operation Warp Speed, during the Trump administration, was sacked as Chairman of the Board of Galvani Bioelectronics about “justified” allegations of sexual harassment, it was announced Wednesday.
Slaoui’s resignation from the board of directors of GalvaniMajority shareholder GlaxoSmithKline came after receiving a letter “with allegations of sexual harassment and inappropriate behavior towards an employee of GSK by Dr. Slaoui, which occurred a few years ago as an employee of GSK”, so GSK.
“After receiving the letter, the GSK board immediately launched an investigation into an experienced law firm to investigate the allegations,” said the GSK statement.
“The investigation into Dr. Slaoui’s behavior has substantiated the allegations and is ongoing.”
GSK said in its statement: “Dr. Slaoui’s behavior is completely unacceptable.”
Emma Winsley, CEO of GSK, revealed in a letter to staff Slaoui’s dismissal, saying, “On a personal level, I am shocked and angry about all of this, but I am determined.”
“I want to make it clear that sexual harassment is strictly prohibited and will not be tolerated,” said Winsley.
She also wrote that GSK will be removing Slaoui’s name from its research and development center in Rockville, Maryland, which is being renamed. It was called the Slaoui Center for Vaccine Research
In its public statement, GSK said that Slaoui’s actions “constitute an abuse of his leadership position, violate company policies and contradict the strong values that define GSK’s culture”.
“The company expects everyone at GSK to behave in accordance with their values, especially their executives, who have the highest standards. Sexual harassment and abuse of leadership positions are strictly prohibited and will not be tolerated.”
He spent 30 years at GSK overseeing vaccine development.
Galvani Bioelectronics is a medical research company focused on developing bioelectronic drugs for the treatment of chronic diseases. It was formed through a partnership between GSK and Verily Life Sciences, previously known as Google Life Sciences. Verily, is a subsidiary of alphabet, the parent of Google.
Slaoui submitted his resignation as Operation Warp Speed in January Chief Advisor to the then-incoming administration of President Joe Biden.
Slaoui was last year criticized when he took on the OWS role because of his drug connections.
At the time of his appointment, he was on the board of directors of Modernafrom which he resigned. He also sold his shares in that company, saying that he had donated its increase in value during the several days he held it during Operation Warp Speed.
But he had refused to sell his GSK stock, calling it his retirement plan.
GSK announced on Wednesday that Christopher Corsico, GSK’s senior vice president of development and current board member of Galvani, has been named Galvani’s new chairman.
GSK also said that Amy Altshul, senior vice president of legal, research and development, and global commercial franchises, has joined Galvani’s board of directors.
This is the latest news. Please try again.